,Kwng-Sook Prk,Jong Hee Kng,b,Dong Keun Hn,b,

aCenter for Biomaterials,Korea Institute of Science and Technology,Hwarangno 14-gil 5,Seongbuk-gu,Seoul 136-791,Republic of Korea

bDepartment of Biomedical Engineering,Korea University of Science and Technology,217 Gajeong-ro,Yuseonggu,Daejeon 305-350,Republic of Korea

Optimized sirolimus-eluting stent by coating asymmetrically with biodegradable and cytocompatible polymers

Seong Min Kima,Kwang-Sook Parka,Jong Hee Kanga, Yoon Ki Jounga,b,Dong Keun Hana,b,*

aCenter for Biomaterials,Korea Institute of Science and Technology,Hwarangno 14-gil 5,Seongbuk-gu,Seoul 136-791,Republic of Korea

bDepartment of Biomedical Engineering,Korea University of Science and Technology,217 Gajeong-ro,Yuseonggu,Daejeon 305-350,Republic of Korea

A R T I C L E I N F O

Article history:

Available online 24 November 2015

Drug-eluting stent

Asymmetric coating

Hyaluronic acid

Sirolimus

Sustained release

Since the approval of the frst stent by the US Food and Drug Administration,stents have been developed from bare metal stents to advanced forms such as drug-eluting stent(DES). However,after being inserted into damaged coronary arteries,even modern DES still has some problems such as late thrombosis or irregular drug release[1,2].

For the effective prevention of these problems,in this study,we fabricated the dual functional stent that has two differently coated surfaces,outer(abluminal)and inner(luminal) sides,as a novel type of DES.Sirolimus(SRL)and dopamineconjugated hyaluronic acid(HA-DA)were coated on abluminal and luminal sides of a bare cobalt-chromium(Co-Cr)alloy stent,respectively.X-ray photoelectron spectroscopy,water contact angle measurement,attenuated total refection-Fourier transform infrared spectroscopy,atomic force microscopy,and feld-emission scanning electron microscopy were performed to characterize each coating.Moreover, we assessed the in vitro drug release patterns using some diverse additives and solvents.According to our results, Co-Cr alloy stents with SRL and HA-DA(SRL/HA stent)were successfully coated on abluminal and luminal sides,respectively.The SRL/HA stent showed more sustained pattern of drug release than only polymer/SRL(PS)coated stents.In addition,the SRL/HA stent had less crack on polymer surfaces after ballooning as compared to PS stent.The results suggest that HA-DA can be used as an additional factor to adjust the drug release pattern and,SRL/HA stent has not only an adequate drug release pattern within desired period at time but also a more fexible effect on preventing the cracking formation.It is expected that this type of DES can be employed to treat the complex lesions by utilizing diverse drugs and biopolymers(Fig.1).

Fig.1–SEM images(A),ATR-FTIR spectra(B),and in vitro release profles of SRL(C).

Acknowledgements

This work was supported by Pioneer Research Center Program (2014M3C1A3056052)of the National Research Foundation of Korea funded by the Ministry of Science,ICT&Future Planning(MSIP)and Core Materials Technology Development Program(10048019)funded by the Ministry of Trade and Industry and Energy(MOTIE),Republic of Korea.

R E F E R E N C E S

[1]Fattori R,Piva T.Drug-eluting stents in vascular intervention. Lancet 2003;36:247–249.

[2]Doyle B,Rihal CS,O’Sullivan CJ,et al.Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents.Circulation 2007;116:2391–2398.

*E-mail address:dkh@kist.re.kr.

Peer review under responsibility of Shenyang Pharmaceutical University.

http://dx.doi.org/10.1016/j.ajps.2015.11.068

1818-0876/?2015 Production and hosting by Elsevier B.V.on behalf of Shenyang Pharmaceutical University.This is an open access article under the CC BY-NC-ND license(http://creativecommons.org/licenses/by-nc-nd/4.0/).